deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT03339726

Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold (PIER)

Randomized, Double-blind, Placebo-Controlled Study of the Efficacy of Phenylephrine HCL Extended-Release 30 mg and Phenylephrine HCL Immediate-Release 12 mg Capsules in Subjects With Nasal Congestion Due to the Common Cold

Sponsor: Johnson & Johnson Consumer Inc. (J&JCI)

Conditions Common Cold
Interventions Marketed Phenylephrine HCl New Formulation Phenylephrine HCl Placebo
Updated 9 times since 2017 Last updated: Jun 3, 2019 Started: Nov 30, 2017 Primary completion: Apr 16, 2018 Completion: Apr 16, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

did not enroll enough subjects in the 2017/2018 cold season, so the study was terminated

Other terminated trials from Johnson & Johnson Consumer Inc. (J&JCI)

See all terminations from Johnson & Johnson Consumer Inc. (J&JCI)

Other Common Cold trials with similar outcome

Browse all Common Cold trials

This PHASE2 trial investigates Common Cold and is currently terminated or withdrawn. Johnson & Johnson Consumer Inc. (J&JCI) leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2017 – ~May 2018 · 5 months · monthly snapshotRecruiting~May 2018 – ~Jun 2018 · 31 days · monthly snapshotSuspended~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshotSuspended~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jul 2019 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Jun 2018 — Jul 2019 [monthly]

    Suspended PHASE2

  3. May 2018 — Jun 2018 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  4. Dec 2017 — May 2018 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Johnson & Johnson Consumer Inc. (J&JCI)
Data source: Johnson & Johnson Consumer and Personal Products Worldwide

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations